Cargando…

Exploration of IMDC model in patients with metastatic renal cell carcinoma using targeted agents: a meta-analysis

PURPOSE: To explore the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model application for predicting outcome of patients with metastatic renal cell carcinoma using targeted agents. MATERIALS AND METHODS: We performed a literature review of 989 articles. The selecting pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Guiya, Chen, Shuqiu, Chen, Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Urologia 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7088475/ https://www.ncbi.nlm.nih.gov/pubmed/31961626 http://dx.doi.org/10.1590/S1677-5538.IBJU.2019.0423

Ejemplares similares

Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma
por: Guida, Annalisa, et al.
Publicado: (2020)

Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC)
por: Yip, Steven M., et al.
Publicado: (2017)

Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era – a multi-institutional retrospective study
por: Kato, Renpei, et al.
Publicado: (2022)

Correction to: Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era – a multi‑institutional retrospective study
por: Kato, Renpei, et al.
Publicado: (2023)

Real-world data on the efficacy and safety of pazopanib in IMDC favorable- and intermediate-risk metastatic renal cell carcinoma: a multicenter retrospective cohort study of Chinese patients
por: Anwaier, Aihetaimujiang, et al.
Publicado: (2022)

C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2022)

PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score
por: Bayoğlu, İbrahim Vedat, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials
por: Manneh, Ray, et al.
Publicado: (2022)

A meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma
por: Wang, Hai-Tao, et al.
Publicado: (2019)

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC
por: Ko, J J, et al.
Publicado: (2014)

The value of renal score in both determining surgical strategies and predicting complications for renal cell carcinoma: A systematic review and meta‐analysis
por: Shi, Naipeng, et al.
Publicado: (2020)

Role of tumor-derived exosomes in metastasis, drug resistance and diagnosis of clear cell renal cell carcinoma
por: Jiang, Tiancheng, et al.
Publicado: (2022)

Inherent characteristics of metachronous metastatic renal cell carcinoma in the era of targeted agents
por: Han, Jang Hee, et al.
Publicado: (2017)

Platelet-derived extracellular vesicles aggravate septic acute kidney injury via delivering ARF6
por: Lu, Xun, et al.
Publicado: (2023)

The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the targeted therapy and immunological therapy era: a systematic review and meta-analysis
por: Chen, Bo, et al.
Publicado: (2023)

Targeted therapy for metastatic renal cell carcinoma
por: Patel, P H, et al.
Publicado: (2006)

Targeted Therapy for Metastatic Renal Carcinoma: an Update
por: da Silva, Rodrigo Donalisio, et al.
Publicado: (2014)

ciRS-7 is a prognostic biomarker and potential gene therapy target for renal cell carcinoma
por: Mao, Weipu, et al.
Publicado: (2021)

Prognostic Significance of Pre- to Postoperative Dynamics of Sarcopenia for Patients with Renal Cell Carcinoma Undergoing Laparoscopic Nephrectomy
por: Chen, Shuqiu, et al.
Publicado: (2022)

Correction to: ciRS-7 is a prognostic biomarker and potential gene therapy target for renal cell carcinoma
por: Mao, Weipu, et al.
Publicado: (2021)

Nutritional screening is strongly associated with overall survival in patients treated with targeted agents for metastatic renal cell carcinoma
por: Gu, Weijie, et al.
Publicado: (2015)

Incidence of immune checkpoint inhibitor–mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score–matched retrospective study
por: Sleiman, Joseph, et al.
Publicado: (2021)

Targeted therapies for previously treated advanced or metastatic renal cell carcinoma: systematic review and network meta-analysis
por: Karner, Charlotta, et al.
Publicado: (2019)

BTG1 potentiates apoptosis and suppresses proliferation in renal cell carcinoma by interacting with PRMT1
por: LIU, CHUNHUI, et al.
Publicado: (2015)

Adoptive Cellular Immunotherapy in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
por: Tang, Xiaoyi, et al.
Publicado: (2013)

The Role of Targeted Therapy in Metastatic Renal Cell Carcinoma
por: Unnithan, Jaya, et al.
Publicado: (2007)

Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma
por: Liu, Yang, et al.
Publicado: (2021)

Effects of stem cell–derived exosome therapy on erectile dysfunction: a systematic review and meta-analysis of preclinical studies
por: Zhu, Yunpei, et al.
Publicado: (2023)

Metastatic polyp of the gallbladder from renal cell carcinoma
por: Shyr, Bor-Uei, et al.
Publicado: (2017)

Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma
por: Deplanque, G, et al.
Publicado: (2004)

The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma
por: Rathi, Nityam, et al.
Publicado: (2019)

Evaluation of Targeted Agents for Advanced and Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis
por: Guo, Tao, et al.
Publicado: (2019)

A Network Meta-Analysis of the Differences in Effectiveness and Safety between Nivolumab and Targeted Drug Therapy in Metastatic Renal Cell Carcinoma
por: Qu, Hongchen, et al.
Publicado: (2022)

Adjuvant targeted therapy combined with surgery for advanced and metastatic renal cell carcinoma: A protocol for systematic review and meta analysis
por: Jin, Hongyu, et al.
Publicado: (2021)

Prognostic value of pretreatment neutrophil count in metastatic renal cell carcinoma: a systematic review and meta-analysis
por: Shen, Jie, et al.
Publicado: (2019)

Circular RNA circPOLR2A promotes clear cell renal cell carcinoma progression by facilitating the UBE3C-induced ubiquitination of PEBP1 and, thereby, activating the ERK signaling pathway
por: Xu, Zhipeng, et al.
Publicado: (2022)

Optimizing targeted drug selection in combination therapy for patients with advanced or metastatic renal cell carcinoma: A systematic review and network meta‐analysis of safety
por: Xie, Ruiyang, et al.
Publicado: (2022)

Targeted agents for the treatment of metastatic melanoma
por: Monzon, Jose G, et al.
Publicado: (2012)

Meta-analysis of gemcitabine plus nab-paclitaxel combined with targeted agents in the treatment of metastatic pancreatic cancer
por: Li, Zhong-Hui, et al.
Publicado: (2022)

High Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio Are Associated With Sarcopenia Risk in Hospitalized Renal Cell Carcinoma Patients
por: Hu, Qiang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hcob6bjbgijnv8vuhgdvpjlqfq